Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 5/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.43 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.42 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.41 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.38 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.38 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL9142238 | 0.84 | QDPR (0.44) | IDO1CYP17A1CYP3A4CYP19A1CYP11B1 | |
| SCHEMBL31618382 | 0.75 | IDO1 (0.61) | IDO1CYP17A1CYP3A4CYP19A1CYP11B1 | |
| SCHEMBL3923741 | 0.72 | IDO1 (0.49) | IDO1CYP3A4 | |
| SCHEMBL12263263 | 0.70 | MKNK1 (0.47) | KDM4E | |
| SCHEMBL9141285 | 0.70 | KMT2A (0.55) | KDM4ECYP17A1DYRK1A | |
| SCHEMBL9564854 | 0.70 | ALDH1A1 (0.44) | KDM4ELMNACYP3A4 | |
| SCHEMBL6764983 | 0.70 | CYP3A4 (0.53) | IDO1KDM4EHSD17B10CYP17A1CYP3A4 | |
| SCHEMBL31618364 | 0.69 | PARP1 (0.41) | IDO1CYP19A1CYP11B2 | |
| SCHEMBL30494467 | 0.69 | RPS6KA3 (0.52) | CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2 | |
| SCHEMBL26462970 | 0.69 | RPS6KA3 (0.52) | CYP17A1CYP3A4CYP19A1CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | GAUDINO JOHN | 2011-03-03 | — | — | US | disclosed |
| EP-2032538-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007146824-A2 | QUINOLINE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053931-A1 | QUINOLINE COMPOUNDS AND METHODS OF USE | TK1, ABL1, ROR1 | IDO1 1283/4885KDM4E 4233/4885LMNA 1139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.